Infectious disease
The companies initiated a Phase II/III trial in Italy, Spain, Germany, France, Japan, Canada and Russia.
The company announced today, in what has been a series of announcements, that it had filed a second clinical trial protocol with the U.S. Food and Drug Administration (FDA) to treat severely sick COVID-19 patients with COVID-19.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 1, 2020.
Results from the trial, which will begin dosing on April 6, aren’t likely until September.
Like many biopharma companies, Amgen is evaluating how the COVID-19 pandemic is affecting its operations, supply chain and clinical trial programs.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 31, 2020.
In addition to the impact on conferences and large meetings, many companies have implemented restrictions on face-to-face meetings between sales reps and clients.
“The adjustments we have made to our studies reflect our foremost concern for the safety and well-being of study participants, clinical investigators and their site staffs, our employees and communities as we face this challenging and unpredictable operating environment,” said Warren Huff, Reata’s chief executive officer and president.
Doudna announced she is converting a 2,500-square-foot scientific lab at Berkeley’s Innovative Genomics Institute into a lab for testing for the novel coronavirus that causes COVID-19.
The healthcare giant said it selected a lead vaccine candidate and plans to begin human testing in September, with first batches available under potential emergency use authorization in the first part of 2021.
PRESS RELEASES